{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:18:51Z","timestamp":1789957131781,"version":"4.0.1"},"reference-count":119,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.bbagen.2023.130499","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T19:12:46Z","timestamp":1698779566000},"page":"130499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Towards development of biobetter: L-asparaginase a case study"],"prefix":"10.1016","volume":"1868","author":[{"given":"Rajan K.","family":"Tripathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Anakha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay H.","family":"Pande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bbagen.2023.130499_bb0005","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/1097-0142(196612)19:12<1813::AID-CNCR2820191208>3.0.CO;2-E","article-title":"Toxic and antineoplastic effects of L-asparaginase. Study of mice with lymphoma and normal monkeys and report on a child with leukemia","volume":"19","author":"Dolowy","year":"1966","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bbagen.2023.130499_bb0010","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/cpt1970113408","article-title":"Clinical pharmacologic studies of L-asparaginase","volume":"11","author":"Ho","year":"1970","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.bbagen.2023.130499_bb0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11274-019-2731-9","article-title":"What makes a good new therapeutic L-asparaginase?","volume":"35","author":"Beckett","year":"2019","journal-title":"World J. Microbiol. Biotechnol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115473","article-title":"The anticancer effect of PASylatedcalreticulin-targeting L-ASNase in solid tumor bearing mice with immunogenic cell death-inducing chemotherapy","volume":"210","author":"Zhang","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0025","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3389\/fonc.2019.01480","article-title":"Asparagine synthetase in cancer: beyond acute lymphoblastic leukemia","volume":"9","author":"Chiu","year":"2020","journal-title":"Front. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.bbagen.2023.130499_bb0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bjm.2016.10.004","article-title":"Current applications and different approaches for microbial l-asparaginase production","volume":"47 Suppl 1","author":"Cachumba","year":"2016","journal-title":"Braz. J. Microbiol."},{"issue":"14","key":"10.1016\/j.bbagen.2023.130499_bb0035","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1021\/bi401692v","article-title":"Structural and kinetic characterization of guinea pig L-asparaginase type III","volume":"53","author":"Schalk","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbagen.2023.130499_bb0040","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1158\/1535-7163.MCT-18-1329","article-title":"Glutaminase activity of L-asparaginase contributes to durable preclinical activity against acute lymphoblastic leukemia","volume":"18","author":"Chan","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"23","key":"10.1016\/j.bbagen.2023.130499_bb0045","first-page":"3596","article-title":"The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells. Blood","volume":"123","author":"Chan","year":"2014","journal-title":"J. Am. Soc. Hematol."},{"issue":"7","key":"10.1016\/j.bbagen.2023.130499_bb0050","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.leukres.2015.04.008","article-title":"Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines","volume":"39","author":"Parmentier","year":"2015","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.bbagen.2023.130499_bb0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of L-asparaginase in childhood ALL","volume":"28","author":"M\u00fcller","year":"1998","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"2","key":"10.1016\/j.bbagen.2023.130499_bb0060","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3109\/10428194.2010.537796","article-title":"Asparaginase revisited","volume":"52","author":"van den Berg","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bbagen.2023.130499_bb0065","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.micres.2018.01.011","article-title":"Marine microbial L-asparaginase: biochemistry, molecular approaches and applications in tumor therapy and in food industry","volume":"208","author":"IzadpanahQeshmi","year":"2018","journal-title":"Microbiol. Res."},{"issue":"11","key":"10.1016\/j.bbagen.2023.130499_bb0070","doi-asserted-by":"crossref","first-page":"19271","DOI":"10.1002\/jcp.28563","article-title":"Bacterial L-asparaginases for cancer therapy: current knowledge and future perspectives","volume":"234","author":"Ghasemian","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"4","key":"10.1016\/j.bbagen.2023.130499_bb0075","first-page":"1565","article-title":"Screening for type II L-asparaginases: lessons from the genus halomonas","volume":"16","author":"Sharafi","year":"2017","journal-title":"Iran. J. Pharm. Res."},{"issue":"3","key":"10.1016\/j.bbagen.2023.130499_bb0080","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jmb.2007.03.061","article-title":"Crystal structure and allosteric regulation of the cytoplasmic Escherichia coli L-asparaginase I","volume":"369","author":"Yun","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0085","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fbioe.2018.00212","article-title":"Development of L-asparaginase biobetters: current research status and review of the desirable quality profiles","volume":"6","author":"Brumano","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbagen.2023.130499_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3109\/07388551.2015.1120705","article-title":"Therapeutic L-asparaginase: upstream, downstream and beyond","volume":"37","author":"Lopes","year":"2017","journal-title":"Crit. Rev. Biotechnol."},{"issue":"6","key":"10.1016\/j.bbagen.2023.130499_bb0095","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-74-6-893","article-title":"L-asparaginase: clinical, biochemical, pharmacological, and immunological studies","volume":"74","author":"Capizzi","year":"1971","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bbagen.2023.130499_bb0100","series-title":"Drug Resistance in Leukemia and Lymphoma III","first-page":"621","article-title":"The three asparaginases: comparative pharmacology and optimal use in childhood leukemia","author":"Asselin","year":"1999"},{"issue":"9","key":"10.1016\/j.bbagen.2023.130499_bb0105","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbagen.2023.130499_bb0110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1078-0432.CCR-19-2975","article-title":"Space for calaspargase? A new asparaginase for acute lymphoblastic leukemia","volume":"26","author":"Lew","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbagen.2023.130499_bb0115","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwiniaasparaginase","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.bbagen.2023.130499_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.902117","article-title":"Current use of asparaginase in acute lymphoblastic leukemia\/lymphoblastic lymphoma","volume":"10","author":"Maese","year":"2022","journal-title":"Front. Pediatr."},{"issue":"2","key":"10.1016\/j.bbagen.2023.130499_bb0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/pbc.22225","article-title":"Erwiniaasparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia","volume":"54","author":"Vrooman","year":"2010","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bbagen.2023.130499_bb0130","first-page":"1","article-title":"The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis","volume":"9","author":"Hu","year":"2019","journal-title":"Heal. Econ. Rev."},{"issue":"7571","key":"10.1016\/j.bbagen.2023.130499_bb0135","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0140-6736(68)90977-X","article-title":"A new L-asparaginase with antitumour activity","volume":"292","author":"Wade","year":"1968","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.bbagen.2023.130499_bb0140","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1182\/blood.V116.21.2134.2134","volume":"116","author":"Salzer","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bbagen.2023.130499_bb0145","first-page":"704","article-title":"Recombinant Erwiniaasparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2\/3 AALL1931 study. Blood","volume":"141","author":"Maese","year":"2023","journal-title":"J. Am. Soc. Hematol."},{"issue":"7","key":"10.1016\/j.bbagen.2023.130499_bb0150","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41433-019-0391-5","article-title":"Biologics, biosilimars, and biobetters: different terms or different drugs?","volume":"33","author":"Sharma","year":"2019","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.bbagen.2023.130499_bb0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.drudis.2021.08.009","article-title":"Building better biobetters: from fundamentals to industrial application","volume":"27","author":"Torres-Obreque","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.bbagen.2023.130499_bb0160","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v10i3.2715","article-title":"Biobetters: are they truly better?","volume":"10","author":"Zaveri","year":"2022","journal-title":"Med. Res. Arch."},{"issue":"21","key":"10.1016\/j.bbagen.2023.130499_bb0165","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S1359-6446(05)03575-0","article-title":"PEGylation, successful approach to drug delivery","volume":"10","author":"Veronese","year":"2005","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbagen.2023.130499_bb0170","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2021.11.016","article-title":"Hypersensitivity to Pegylated E. coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno toxicity working group","volume":"162","author":"Brigitha","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbagen.2023.130499_bb0175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0006-291X(78)91002-1","article-title":"Modification of E. coli L-asparaginase with polyethylene glycol: disappearance of binding ability to anti-asparaginase serum","volume":"83","author":"Ashihara","year":"1978","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.bbagen.2023.130499_bb0180","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bbagen.2023.130499_bb0185","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","article-title":"Pegaspargase: a review of clinical studies","volume":"55","author":"Graham","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.bbagen.2023.130499_bb0190","first-page":"1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children\u2019s cancer group study. Blood","volume":"99","author":"Avramis","year":"2002","journal-title":"J. Am. Soc. Hematol."},{"issue":"8","key":"10.1016\/j.bbagen.2023.130499_bb0195","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: pegaspargase (Oncaspar\u00ae) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"Dinndorf","year":"2007","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.bbagen.2023.130499_bb0200","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1158\/1078-0432.CCR-19-1255","article-title":"FDA approval summary: calaspargasepegol-mknl for treatment of acute lymphoblastic leukemia in children and young adults","volume":"26","author":"Li","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"34","key":"10.1016\/j.bbagen.2023.130499_bb0205","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargasepegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from children\u2019s oncology group study AALL07P4","volume":"32","author":"Angiolillo","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.bbagen.2023.130499_bb0210","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1200\/JCO.20.03692","article-title":"Efficacy and toxicity of pegaspargase and calaspargasepegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001","volume":"39","author":"Vrooman","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbagen.2023.130499_bb0215","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1517\/14712598.2016.1165661","article-title":"Half-life extended biotherapeutics","volume":"16","author":"Kontermann","year":"2016","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.bbagen.2023.130499_bb0220","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1248\/bpb.b13-00661","article-title":"Discussion about several potential drawbacks of PEGylated therapeutic proteins","volume":"37","author":"Zhang","year":"2014","journal-title":"Biol. Pharm. Bull."},{"issue":"14","key":"10.1016\/j.bbagen.2023.130499_bb0225","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1111\/febs.16042","article-title":"Structural and biochemical properties of L-asparaginase","volume":"288","author":"Lubkowski","year":"2021","journal-title":"FEBS J."},{"issue":"19","key":"10.1016\/j.bbagen.2023.130499_bb0230","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1021\/bi0029595","article-title":"Structural basis for the activity and substrate specificity of Erwiniachrysanthemi L-asparaginase","volume":"40","author":"Aghaiypour","year":"2001","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.bbagen.2023.130499_bb0235","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1110\/ps.9.10.2009","article-title":"Engineering the substrate specificity of Escherichia coli asparaginase II. Selective reduction of glutaminase activity by amino acid replacements at position 248","volume":"9","author":"Derst","year":"2000","journal-title":"Protein Sci."},{"issue":"2","key":"10.1016\/j.bbagen.2023.130499_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117025","article-title":"Engineering of Helicobacter pylori L-asparaginase: characterization of two functionally distinct groups of mutants","volume":"10","author":"Maggi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2023.130499_bb0245","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1096\/fj.11-191254","article-title":"Hyperthermophilic asparaginase mutants with enhanced substrate affinity and antineoplastic activity: structural insights on their mechanism of action","volume":"26","author":"Bansal","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.bbagen.2023.130499_bb0250","doi-asserted-by":"crossref","DOI":"10.5812\/ijcm.5785","article-title":"Applying bioinformatic tools for modeling and modifying Type II E. colil-Asparginase to present a better therapeutic agent\/drug for acute lymphoblastic leukemia","volume":"10","author":"Mahboobi","year":"2017","journal-title":"Int. J. Cancer Manag."},{"key":"10.1016\/j.bbagen.2023.130499_bb0255","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1016\/j.ijbiomac.2018.09.015","article-title":"Selective reduction in glutaminase activity of l\u2019Asparaginase by asparagine 248 to serine mutation: a combined computational and experimental effort in blood cancer treatment","volume":"120","author":"Aghaeepoor","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.bbagen.2023.130499_bb0260","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1038\/s41598-017-15075-4","article-title":"A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro","volume":"7","author":"Maggi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbagen.2023.130499_bb0265","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1042\/BJ20061708","article-title":"Tailoring structure-function properties of L-asparaginase: engineering resistance to trypsin cleavage","volume":"404","author":"Kotzia","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbagen.2023.130499_bb0270","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.biortech.2017.05.057","article-title":"Genetic and metabolic engineering approaches for the production and delivery of L-asparaginases: an overview","volume":"245","author":"Vidya","year":"2017","journal-title":"Bioresour. Technol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0275","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.biochi.2014.07.024","article-title":"Interplay between amino acid residues at positions 192 and 115 in modulating hydrolytic activities of human paraoxonase 1","volume":"105","author":"Bajaj","year":"2014","journal-title":"Biochimie"},{"key":"10.1016\/j.bbagen.2023.130499_bb0280","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s12010-017-2424-5","article-title":"Towards understanding the catalytic mechanism of human paraoxonase 1: experimental and in silico mutagenesis studies","volume":"182","author":"Tripathy","year":"2017","journal-title":"Appl. Biochem. Biotechnol."},{"issue":"4","key":"10.1016\/j.bbagen.2023.130499_bb0285","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1073\/pnas.1014739108","article-title":"Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift","volume":"108","author":"Cantor","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3\u20134","key":"10.1016\/j.bbagen.2023.130499_bb0290","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molcatb.2011.05.003","article-title":"Engineering substrate specificity of E. carotovora L-asparaginase for the development of biosensor","volume":"72","author":"Kotzia","year":"2011","journal-title":"J. Mol. Catal. B Enzym."},{"issue":"5","key":"10.1016\/j.bbagen.2023.130499_bb0295","first-page":"1614","article-title":"Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity. Blood","volume":"117","author":"Offman","year":"2011","journal-title":"J. Am. Soc. Hematol."},{"issue":"34","key":"10.1016\/j.bbagen.2023.130499_bb0300","doi-asserted-by":"crossref","first-page":"17664","DOI":"10.1074\/jbc.M116.728485","article-title":"Design and characterization of erwiniachrysanthemi L-asparaginase variants with diminished l-glutaminase activity","volume":"291","author":"Nguyen","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.bbagen.2023.130499_bb0305","first-page":"1964","article-title":"A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase","volume":"119","author":"Patel","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.bbagen.2023.130499_bb0310","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1111\/j.1742-4658.2009.06910.x","article-title":"Engineering thermal stability of L-asparaginase by in vitro directed evolution","volume":"276","author":"Kotzia","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.bbagen.2023.130499_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.enzmictec.2015.11.010","article-title":"Enhanced catalysis of L-asparaginase from Bacillus licheniformis by a rational redesign","volume":"86","author":"Sudhir","year":"2016","journal-title":"Enzym. Microb. Technol."},{"issue":"6","key":"10.1016\/j.bbagen.2023.130499_bb0320","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1074\/jbc.M113.486530","article-title":"Mutations in subunit interface and B-cell epitopes improve antileukemic activities of Escherichia coli asparaginase-II: evaluation of immunogenicity in mice","volume":"289","author":"Mehta","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2023.130499_bb0325","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1385\/MB:33:1:57","article-title":"Probing the antigenicity of E. coli L-asparaginase by mutational analysis","volume":"33","author":"Jianhua","year":"2006","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0330","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12033-014-9819-0","article-title":"Identification of functional regions in the Rhodospirillumrubrum L-asparaginase by site-directed mutagenesis","volume":"57","author":"Pokrovskaya","year":"2015","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0335","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.mehy.2018.01.004","article-title":"Novel mutant of Escherichia coli asparaginase II to reduction of the glutaminase activity in treatment of acute lymphocytic leukemia by molecular dynamics simulations and QM-MM studies","volume":"112","author":"Ardalan","year":"2018","journal-title":"Med. Hypotheses"},{"issue":"8","key":"10.1016\/j.bbagen.2023.130499_bb0340","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/MPH.0b013e31822aa4ec","article-title":"In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia","volume":"33","author":"Ramya","year":"2011","journal-title":"J. Pediatr. Hematol. Oncol."},{"issue":"24","key":"10.1016\/j.bbagen.2023.130499_bb0345","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.3390\/molecules27248859","article-title":"Impact of N-linked glycosylation on therapeutic proteins","volume":"27","author":"Chen","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bbagen.2023.130499_bb0350","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.copbio.2009.10.009","article-title":"Pharmacological significance of glycosylation in therapeutic proteins","volume":"20","author":"Li","year":"2009","journal-title":"Curr. Opin. Biotechnol."},{"issue":"8","key":"10.1016\/j.bbagen.2023.130499_bb0355","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/jps.20319","article-title":"Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins","volume":"94","author":"Sinclair","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.bbagen.2023.130499_bb0360","series-title":"Chronic Renal Disease","first-page":"624","article-title":"Management of anemia in chronic kidney disease","author":"Fernandez","year":"2015"},{"key":"10.1016\/j.bbagen.2023.130499_bb0365","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0141-0229(94)90149-X","article-title":"Glycosylation of recombinant proteins: problems and prospects","volume":"16","author":"Jenkins","year":"1994","journal-title":"Enzym. Microb. Technol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0370","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nbt0896-975","article-title":"Getting the glycosylation right: implications for the biotechnology industry","volume":"14","author":"Jenkins","year":"1996","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0375","article-title":"Chemical modification of proteins\u2013challenges and trends in the start of the 2020s","author":"Fischer","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.bbagen.2023.130499_bb0380","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9225647","article-title":"Carboxymethyl dextran-based nanomicelle coatings on microarc oxidized titanium surface for percutaneous implants: drug release, antibacterial properties, and biocompatibility","volume":"2022","author":"Ye","year":"2022","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bbagen.2023.130499_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2019.113537","article-title":"Effect of chemical modification with carboxymethyl dextran on kinetic and structural properties of L-asparaginase","volume":"591","author":"Chahardahcherik","year":"2020","journal-title":"Anal. Biochem."},{"issue":"5","key":"10.1016\/j.bbagen.2023.130499_bb0390","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/10826068.2013.833110","article-title":"Chemical modification of L-asparaginase from Cladosporium sp. for improved activity and thermal stability","volume":"44","author":"Mohan Kumar","year":"2014","journal-title":"Prep. Biochem. Biotechnol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0395","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/524155a","article-title":"Don\u2019t waste seafood waste: turning cast-off shells into nitrogen-rich chemicals would benefit economies and the environment","volume":"524","author":"Yan","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbagen.2023.130499_bb0400","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0144-8617(83)90012-7","article-title":"Chitin and its derivatives: new trends of applied research","volume":"3","author":"Muzzarelli","year":"1983","journal-title":"Carbohydr. Polym."},{"issue":"12","key":"10.1016\/j.bbagen.2023.130499_bb0405","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1021\/cr030441b","article-title":"Chitosan chemistry and pharmaceutical perspectives","volume":"104","author":"Kumar","year":"2004","journal-title":"Chem. Rev."},{"issue":"6","key":"10.1016\/j.bbagen.2023.130499_bb0410","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3109\/10731199609118882","article-title":"The chemical modification of E. coli L-asparaginase by N, O-carboxymethyl chitosan","volume":"24","author":"Qian","year":"1996","journal-title":"Artif. Cells Blood Substit. Biotechnol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.imu.2021.100689","article-title":"Investigating the protective effects of carbohydrate coatings on the structure and dynamic of L-asparaginase against heat stress; a molecular dynamic simulation","volume":"25","author":"Moradi","year":"2021","journal-title":"Inform. Med. Unlocked"},{"issue":"2","key":"10.1016\/j.bbagen.2023.130499_bb0420","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2009.10.004","article-title":"HPMA copolymers: origins, early developments, present, and future","volume":"62","author":"Kope\u010dek","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"16","key":"10.1016\/j.bbagen.2023.130499_bb0425","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1016\/j.biomaterials.2003.10.003","article-title":"The use of PVP as a polymeric carrier to improve the plasma half-life of drugs","volume":"25","author":"Kaneda","year":"2004","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.bbagen.2023.130499_bb0430","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1021\/acs.biomac.8b01020","article-title":"Impact of polymer bioconjugation on protein stability and activity investigated with discrete conjugates: alternatives to PEGylation","volume":"19","author":"Morgenstern","year":"2018","journal-title":"Biomacromolecules"},{"issue":"9","key":"10.1016\/j.bbagen.2023.130499_bb0435","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1039\/c0py00406e","article-title":"Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure\u2013property relationships to better defined therapeutics","volume":"2","author":"Barz","year":"2011","journal-title":"Polym. Chem."},{"issue":"6","key":"10.1016\/j.bbagen.2023.130499_bb0440","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.copbio.2011.06.012","article-title":"Strategies for extended serum half-life of protein therapeutics","volume":"22","author":"Kontermann","year":"2011","journal-title":"Curr. Opin. Biotechnol."},{"issue":"4","key":"10.1016\/j.bbagen.2023.130499_bb0445","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-015-0133-6","article-title":"Fusion proteins for half-life extension of biologics as a strategy to make biobetters","volume":"29","author":"Strohl","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.bbagen.2023.130499_bb0450","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13205-021-02999-y","article-title":"Expanding the bio-catalysis scope and applied perspectives of nanocarrier immobilized asparaginases","volume":"11","author":"Rafeeq","year":"2021","journal-title":"3 Biotech"},{"issue":"17","key":"10.1016\/j.bbagen.2023.130499_bb0455","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1016\/j.biomaterials.2003.10.019","article-title":"Immobilization of L-asparaginase on the microparticles of the natural silk sericin protein and its characters","volume":"25","author":"Zhang","year":"2004","journal-title":"Biomaterials"},{"issue":"20","key":"10.1016\/j.bbagen.2023.130499_bb0460","doi-asserted-by":"crossref","first-page":"9728","DOI":"10.1039\/c0sm01332c","article-title":"Highly efficient processing of silk fibroin nanoparticle-L-asparaginasebioconjugates and their characterization as a drug delivery system","volume":"7","author":"Zhang","year":"2011","journal-title":"Soft Matter"},{"issue":"3\u20134","key":"10.1016\/j.bbagen.2023.130499_bb0465","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jbiotec.2009.03.020","article-title":"Synthesis, physicochemical and immunological properties of oxidized inulin\u2013L-asparaginasebioconjugate","volume":"141","author":"Tabandeh","year":"2009","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0470","first-page":"93","article-title":"L-asparaginase immobilized p(HEMA-GMA) cryogels: a recent study for biochemical, thermodynamic and kinetic parameters","author":"Noma","year":"2021","journal-title":"Polym. Test."},{"key":"10.1016\/j.bbagen.2023.130499_bb0475","first-page":"226","article-title":"A rational approach for 3D recognition and removal of L-asparagine via molecularly imprinted membranes","author":"Acet","year":"2023","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bbagen.2023.130499_bb0480","article-title":"A new design to enhance the enzyme activities: investigation of L-asparaginase catalytic performance by IMAC effect on g-C3N4 nanolayers","author":"Sert","year":"2023","journal-title":"Catal. Lett."},{"key":"10.1016\/j.bbagen.2023.130499_bb0485","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10562-023-04418-8","article-title":"Design of enhanced smart delivery systems for therapeutic enzymes: kinetic and release performance of dual effected enzyme-loaded nanopolymers","volume":"153","author":"Acet","year":"2023","journal-title":"Catal. Lett."},{"issue":"9","key":"10.1016\/j.bbagen.2023.130499_bb0490","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.addr.2012.01.005","article-title":"Virus-based nanocarriers for drug delivery","volume":"64","author":"Ma","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.bbagen.2023.130499_bb0495","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2019-0001","article-title":"Future of cancer immunotherapy using plant virus-based nanoparticles","volume":"5","author":"Shoeb","year":"2019","journal-title":"Future Sci. OA"},{"issue":"5","key":"10.1016\/j.bbagen.2023.130499_bb0500","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3390\/pharmaceutics13050604","article-title":"Asparaginase-phage P22 nanoreactors: toward a biobetter development for acute lymphoblastic leukemia treatment","volume":"13","author":"D\u00edaz-Barriga","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.bbagen.2023.130499_bb0505","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/pharmaceutics12050435","article-title":"Erythrocytes as carriers of therapeutic enzymes","volume":"12","author":"Bax","year":"2020","journal-title":"Pharmaceutics"},{"issue":"4254","key":"10.1016\/j.bbagen.2023.130499_bb0510","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1126\/science.821145","article-title":"Asparaginase entrapped in red blood cells: action and survival","volume":"193","author":"Updike","year":"1976","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bbagen.2023.130499_bb0515","first-page":"679","article-title":"Infusion of red blood cell-loaded asparaginase in monkey: immunologic, metabolic, and toxicologic consequences","volume":"101","author":"Updike","year":"1983","journal-title":"J. Lab. Clin. Med."},{"issue":"3","key":"10.1016\/j.bbagen.2023.130499_bb0520","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1124\/jpet.119.257063","article-title":"Protein chimerization: a new frontier for engineering protein therapeutics with improved pharmacokinetics","volume":"370","author":"Iyengar","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bbagen.2023.130499_bb0525","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/17425247.2014.952627","article-title":"Blood\u2013brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody","volume":"12","author":"Pardridge","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.bbagen.2023.130499_bb0530","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/antib8010005","article-title":"Current approaches and future perspectives for nanobodies in stroke diagnostic and therapy","volume":"8","author":"Jank","year":"2019","journal-title":"Antibodies"},{"issue":"42","key":"10.1016\/j.bbagen.2023.130499_bb0535","doi-asserted-by":"crossref","first-page":"29014","DOI":"10.1074\/jbc.M114.602474","article-title":"Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis","volume":"289","author":"Harari","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.bbagen.2023.130499_bb0540","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050630","article-title":"GLP2-2G-XTEN: a pharmaceutical protein with improved serum half-life and efficacy in a rat Crohn\u2019s disease model","volume":"7","author":"Alters","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.bbagen.2023.130499_bb0545","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1073\/pnas.89.10.4304","article-title":"Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit","volume":"89","author":"Fares","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.bbagen.2023.130499_bb0550","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/BA19990062","article-title":"Selecting and expressing protective single-chain Fv fragment to stabilize L-asparaginase against inactivation by trypsin","volume":"31","author":"Guo","year":"2000","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"1","key":"10.1016\/j.bbagen.2023.130499_bb0555","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1006\/bbrc.2000.3434","article-title":"Characterization of L-asparaginase fused with a protective ScFv and the protection mechanism","volume":"276","author":"Guo","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"22","key":"10.1016\/j.bbagen.2023.130499_bb0560","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.3390\/cancers13225637","article-title":"A targeted catalytic nanobody (T-CAN) with asparaginolytic activity","volume":"13","author":"Maggi","year":"2021","journal-title":"Cancers"},{"issue":"35","key":"10.1016\/j.bbagen.2023.130499_bb0565","doi-asserted-by":"crossref","first-page":"9127","DOI":"10.1016\/j.biomaterials.2012.08.063","article-title":"A protein delivery system using 30Kc19 cell-penetrating protein originating from silkworm","volume":"33","author":"Park","year":"2012","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.bbagen.2023.130499_bb0570","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.biomaterials.2013.11.001","article-title":"Enzyme delivery using the 30Kc19 protein and human serum albumin nanoparticles","volume":"35","author":"Lee","year":"2014","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bbagen.2023.130499_bb0575","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/21691401.2022.2126851","article-title":"Enhanced anti-cancer effect using MMP-responsive L-asparaginase fused with cell-penetrating 30Kc19 protein","volume":"50","author":"Ryu","year":"2022","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0580","series-title":"Chemical Synthesis of Cu-64asp (Copper-64asparaginase; [64cu]asparaginase) for Pet Scans and Radiotheraphy Application","author":"Valentini","year":"2023"},{"key":"10.1016\/j.bbagen.2023.130499_bb0585","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1007\/s00253-021-11359-y","article-title":"L-asparaginase production review: bioprocess design and biochemical characteristics","volume":"105","author":"Castro","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.bbagen.2023.130499_bb0590","first-page":"191","article-title":"Comparative structural and kinetic study for development of a novel candidate L-asparaginase based pharmaceutical","author":"Berin","year":"2023","journal-title":"Biochem. Eng. J."},{"issue":"1","key":"10.1016\/j.bbagen.2023.130499_bb0595","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1038\/s41598-017-10758-4","article-title":"Discovery of human-like L-asparaginases with potential clinical use by directed evolution","volume":"7","author":"Rigouin","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416523001976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416523001976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:17:36Z","timestamp":1759637856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304416523001976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0304416523001976"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagen.2023.130499","relation":{},"ISSN":["0304-4165"],"issn-type":[{"value":"0304-4165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards development of biobetter: L-asparaginase a case study","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - General Subjects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagen.2023.130499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"130499"}}